Enfortumab vedotin plus pembrolizumab for recurrent metastatic urothelial carcinoma following adjuvant nivolumab
Lan Inoki, Saizo Fujimoto, Mamoru Hashimoto, Yutaka Yamamoto et autres
Adjuvant nivolumab is an established postoperative treatment for high-risk urothelial carcinoma, but evidence for subsequent enfortumab vedotin plus pembrolizumab (EVP) after recurrence is limited. We retrospectively evaluated 17 patients with locally advanced or metastatic urothelial carcinoma who received EVP after recurrence following …
jp (code pays fourni par la source)
0 citations
Japanese Journal of Clinical Oncology